Abstract
TGF-β-activated kinase-1 (TAK1) is a kinase that has recently been shown to promote cell survival in KRas-dependent colon cancers, and therefore it is a potential novel therapeutic target for these resistant tumors. Previous studies in colon cancer cell lines have demonstrated that TAK1 inhibition leads to increased generation of reactive oxygen species (ROS). We hypothesize that inhibition of TAK1 reduces colon cancer cell survival by inducing thiol-dependent oxidative stress in KRas-dependent colon cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
